Table 2 Phenotypic features of the patients compared to the controls (median and 10–90% percentiles). MDS cases are divided between those with normal and increased BM monocytes.

From: A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes

  Controls N = 15 MDS with normal percentage of monocytes n = 69 MDS with increased monocytes n = 26 p values***
SSC Gran/lympho ratio 8.7 (6.9–9.5) 7.3 (4.7–9.6) 6.5 (4.6–9.2) 0.009
% total monocytes 3.7 (2.0–5.6) 1.9 (0.5–4.4) 9.1 (5.7–19.1)  < 0.0001
% classical monocytes* 3.46 (1.8–5.1) 1.46 (0.39–3.55) 6.7 (4.5–16.8)  < 0.0001
% classical monocytes** 92% (83–95) 85% (60–95) 84% (53–97) 0.52
% CD16+ monocytes* 0.29 (0.1–0.5) 0.19 (0.08–1.0) 1.1 (0.30–4.7)  < 0.0001
% CD16+ monocytes** 7.6 (4.9–16.8) 15% (5–40) 15% (3–45) 0.49
% B-cell progenitors* 0.18 (0.05–0.58) 0.0 (0.0–0.23) 0.0 (0.0–0.08)  < 0.0001
% CD34+ myeloblasts* 0.7 (0.34–1.0) 0.78 (0.15–6.8) 0.26 (0.08–4.5) 0.008
  1. *Among total nucleated cells (TNCs), **among total monocytes, *** comparing all 3 groups.